» Articles » PMID: 27880817

Melissa Officinalis Protects Against Doxorubicin-Induced Cardiotoxicity in Rats and Potentiates Its Anticancer Activity on MCF-7 Cells

Overview
Journal PLoS One
Date 2016 Nov 24
PMID 27880817
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Cardiotoxicity is a limiting factor of doxorubicin (DOX)-based anticancer therapy. Due to its beneficial effects, we investigated whether standardized extract of Melissa officinalis (MO) can attenuate doxorubicin-induced cardiotoxicity and can potentiate the efficacy of DOX against human breast cancer cells. MO was administered orally to male albino rats once daily for 10 consecutive days at doses of 250, 500 and 750 mg/kg b.wt. DOX (15 mg/kg b.wt. i.p.) was administered on the 8th day. MO protected against DOX-induced leakage of cardiac enzymes and histopathological changes. MO ameliorated DOX-induced oxidative stress as evidenced by decreasing lipid peroxidation, protein oxidation and total oxidant capacity depletion and by increasing antioxidant capacity. Additionally, MO pretreatment inhibited inflammatory responses to DOX by decreasing the expressions of nuclear factor kappa-B, tumor necrosis factor-alpha and cyclooxygenase-2 and the activity of myeloperoxidase. MO ameliorated DOX-induced apoptotic tissue damage in heart of rats. In vitro study showed that MO augmented the anticancer efficacy of DOX in human breast cancer cells (MCF-7) and potentiated oxidative damage and apoptosis. Thus, combination of DOX and MO may prove future cancer treatment protocols safer and more efficient.

Citing Articles

Ameliorates Doxorubicin-Induced Nephrotoxicity and Potentiates Its Therapeutic Efficacy Targeting SIRT1/Nrf2, Oxidative Stress, Inflammation, and Apoptosis.

Mohmmed Hegab A, Hassanin S, Mekky R, Abuzahrah S, Hamza A, Talaat I Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006061 PMC: 11859695. DOI: 10.3390/ph18020248.


Small Extracellular Vesicles from Breast Cancer Cells Induce Cardiotoxicity.

Osorio-Mendez J, Gomez-Grosso L, Montoya-Ortiz G, Novoa-Herran S, Dominguez-Romero Y Int J Mol Sci. 2025; 26(3).

PMID: 39940718 PMC: 11816698. DOI: 10.3390/ijms26030945.


Therapeutic Applications of Rosmarinic Acid in Cancer-Chemotherapy-Associated Resistance and Toxicity.

Villegas C, Cortez N, Ogundele A, Burgos V, Pardi P, Cabrera-Pardo J Biomolecules. 2024; 14(7).

PMID: 39062581 PMC: 11274592. DOI: 10.3390/biom14070867.


Cardioprotective Potential of Leaf Extract Loaded Niosomes Nanoparticles - Against Doxorubicin Toxicity In Rats.

Mohamad E, Ahmed S, Masoud M, Mohamed F, Mohammed H Curr Pharm Biotechnol. 2024; 26(2):289-301.

PMID: 38918977 DOI: 10.2174/0113892010303097240605105013.


5'-Methylthioadenosine strongly suppresses RANKL-induced osteoclast differentiation and function via inhibition of RANK-NFATc1 signalling pathways.

Rattajak P, Aroonkesorn A, Smythe C, Wititsuwannakul R, Pitakpornpreecha T Heliyon. 2023; 9(11):e22365.

PMID: 38099006 PMC: 10720268. DOI: 10.1016/j.heliyon.2023.e22365.


References
1.
Bjelogrlic S, Radic J, Jovic V, Radulovic S . Activity of d,l-alpha-tocopherol (vitamin E) against cardiotoxicity induced by doxorubicin and doxorubicin with cyclophosphamide in mice. Basic Clin Pharmacol Toxicol. 2005; 97(5):311-9. DOI: 10.1111/j.1742-7843.2005.pto_166.x. View

2.
Hillegass L, Griswold D, Brickson B . Assessment of myeloperoxidase activity in whole rat kidney. J Pharmacol Methods. 1990; 24(4):285-95. DOI: 10.1016/0160-5402(90)90013-b. View

3.
Reznick A, Packer L . Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol. 1994; 233:357-63. DOI: 10.1016/s0076-6879(94)33041-7. View

4.
Li W, Xu B, Xu J, Wu X . Procyanidins produce significant attenuation of doxorubicin-induced cardiotoxicity via suppression of oxidative stress. Basic Clin Pharmacol Toxicol. 2009; 104(3):192-7. DOI: 10.1111/j.1742-7843.2008.00358.x. View

5.
de Sousa A, Alviano D, Blank A, Barreto Alves P, Alviano C, Gattass C . Melissa officinalis L. essential oil: antitumoral and antioxidant activities. J Pharm Pharmacol. 2004; 56(5):677-81. DOI: 10.1211/0022357023321. View